Vistagen Therapeutics, Inc. (VTGN)
0.2388
0.00 (0.00%)
USD |
NASDAQ |
Sep 10, 14:58
Vistagen Therapeutics Debt to Equity Ratio : 0.032 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.032 |
| March 31, 2026 | 0.0294 |
| December 31, 2025 | 0.028 |
| September 30, 2025 | 0.0281 |
| June 30, 2025 | 0.0415 |
| December 31, 2024 | 0.0211 |
| September 30, 2024 | 0.0193 |
| June 30, 2024 | 0.019 |
| March 31, 2024 | 0.0185 |
| December 31, 2023 | 0.0183 |
| September 30, 2023 | 0.0668 |
| June 30, 2023 | 0.4795 |
| March 31, 2023 | 0.2251 |
| December 31, 2022 | 0.1522 |
| September 30, 2022 | 0.1205 |
| June 30, 2022 | 0.0865 |
| March 31, 2022 | 0.047 |
| December 31, 2021 | 0.0393 |
| September 30, 2021 | 0.0439 |
| June 30, 2021 | 0.0424 |
| March 31, 2021 | 0.0404 |
| December 31, 2020 | 0.0416 |
| September 30, 2020 | 1.024 |
| June 30, 2020 | -0.8047 |
| March 31, 2020 | -0.7142 |
| Date | Value |
|---|---|
| December 31, 2019 | -0.6854 |
| September 30, 2019 | -1.194 |
| June 30, 2019 | 2.762 |
| March 31, 2019 | 0.0094 |
| December 31, 2018 | 0.0349 |
| September 30, 2018 | 0.0317 |
| June 30, 2018 | 0.0597 |
| March 31, 2018 | 0.0095 |
| December 31, 2017 | 0.0055 |
| September 30, 2017 | -0.0708 |
| June 30, 2017 | -0.2953 |
| March 31, 2017 | 0.1122 |
| December 31, 2016 | 0.0139 |
| September 30, 2016 | 0.0175 |
| June 30, 2016 | 0.0173 |
| March 31, 2016 | -0.0201 |
| December 31, 2015 | -0.0541 |
| September 30, 2015 | -0.093 |
| June 30, 2015 | -0.3904 |
| March 31, 2015 | -0.5862 |
| December 31, 2014 | -0.5622 |
| September 30, 2014 | -0.5563 |
| June 30, 2014 | -0.4826 |
| March 31, 2014 | -0.4614 |
| December 31, 2013 | -0.4804 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
| Anika Therapeutics, Inc. | 0.1839 |
| Savara, Inc. | 0.2117 |
| Vericel Corp. | 0.2556 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 35.74M |
| Total Liabilities (Quarterly) | 11.26M |
| Shareholders Equity (Quarterly) | 24.48M |
| Current Ratio | 3.066 |
| Net Debt Paydown Yield | 1.85% |